TY - THES AU - Kolonics-Farkas, Abigél Margit TI - PULMONARY ASSESSMENT OF PATIENTS WITH MARFAN SYNDROME PY - 2022 DO - 10.14753/SE.2022.2572 UR - https://m2.mtmt.hu/api/publication/33734711 ID - 33734711 LA - English DB - MTMT ER - TY - JOUR AU - Seidl, Elias AU - Schwerk, Nicolaus AU - Carlens, Julia AU - Wetzke, Martin AU - Cunningham, Steve AU - Emiralioglu, Nagehan AU - Kiper, Nural AU - Lange, Joanna AU - Krenke, Katarzyna AU - Ullmann, Nicola AU - Krikovszky, Dóra AU - Maqhuzu, Phillen AU - Griese, Charlotte A. AU - Schwarzkopf, Larissa AU - Griese, Matthias ED - Kolonics-Farkas, Abigél Margit / Collaborator TI - Healthcare resource utilisation and medical costs for children with interstitial lung diseases (chILD) in Europe JF - THORAX J2 - THORAX VL - 78 PY - 2022 IS - 8 SP - 781 EP - 789 PG - 9 SN - 0040-6376 DO - 10.1136/thoraxjnl-2021-217751 UR - https://m2.mtmt.hu/api/publication/32736492 ID - 32736492 LA - English DB - MTMT ER - TY - JOUR AU - Nagy, Alexandra AU - Palmer, Erik József AU - Bárczi, Enikő AU - Kolonics-Farkas, Abigél Margit AU - Erdélyi, Tamás AU - Vincze, Krisztina AU - Eszes, Noémi AU - Bohács, Anikó AU - Müller, Veronika TI - Lung functional decline in patients with Interstitial Pneumonia with Autoimmune Features (IPAF) JF - EUROPEAN RESPIRATORY JOURNAL J2 - EUR RESPIR J VL - 58 PY - 2021 IS - Suppl. 65 SN - 0903-1936 DO - 10.1183/13993003.congress-2021.PA2376 UR - https://m2.mtmt.hu/api/publication/32856970 ID - 32856970 LA - English DB - MTMT ER - TY - JOUR AU - Kolonics-Farkas, Abigél Margit AU - Šterclová, Martina AU - Mogulkoc, Nesrin AU - Lewandowska, Katarzyna AU - Müller, Veronika AU - Hájková, Marta AU - Kramer, Mordechai AU - Jovanovic, Dragana AU - Tekavec-Trkanjec, Jasna AU - Studnicka, Michael AU - Stoeva, Natalia AU - Littnerová, Simona AU - Vašáková, Martina TI - Differences in Baseline Characteristics and Access to Treatment of Newly Diagnosed Patients With IPF in the EMPIRE Countries JF - FRONTIERS IN MEDICINE J2 - FRONT MED VL - 8 PY - 2021 PG - 11 SN - 2296-858X DO - 10.3389/fmed.2021.729203 UR - https://m2.mtmt.hu/api/publication/32551768 ID - 32551768 N1 - Department of Pulmonology, Semmelweis University, Budapest, Hungary Department of Respiratory Diseases of the First Faculty of Medicine Charles University, University Thomayer Hospital, Prague, Czech Republic Department of Pulmonary Medicine, Ege University Medical School, Izmir, Turkey First Department of Pulmonary Diseases, Institute of Tuberculosis and Lung Diseases, Warsaw, Poland Clinic of Pneumology and Phthisiology, University Hospital Bratislava, Bratislava, Slovakia Rabin Medical Center, Institute of Pulmonary Medicine, Petah Tikva, Israel Internal Medicine Clinic “Akta Medica”, Belgrade, Serbia Pulmonary Department, University Hospital Dubrava, Zagreb, Croatia Clinical Research Centre Salzburg, Salzburg, Austria Tokuda Hospital Sofia, Sofia, Bulgaria Faculty of Medicine, Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic Cited By :1 Export Date: 24 April 2023 Correspondence Address: Müller, V.; Department of Pulmonology, Hungary; email: muller.veronika@med.semmelweis-univ.hu Chemicals/CAS: nintedanib, 928326-83-4, 656247-17-5, 656247-18-6; pirfenidone, 53179-13-8 Funding details: Roche Funding details: F. Hoffmann-La Roche Funding details: Boehringer Ingelheim Funding text 1: The EMPIRE registry and this investigator-initiated study have been supported with funding from Boehringer Ingelheim (BI) and F. Hoffman-La Roche (Roche). BI and Roche had no role in the study design, analysis, or interpretation of the results. BI and Roche were given the opportunity to review the manuscript for medical and scientific accuracy as it relates to BI and Roche substances and intellectual property considerations. LA - English DB - MTMT ER - TY - JOUR AU - Nagy, Alexandra AU - Nagy, Tamás AU - Kolonics-Farkas, Abigél Margit AU - Eszes, Noémi AU - Vincze, Krisztina AU - Bárczi, Enikő AU - Tárnoki, Ádám Domonkos AU - Tárnoki, Dávid László AU - Nagy, György AU - Kiss, Emese AU - Maurovich-Horvat, Pál AU - Bohács, Anikó AU - Müller, Veronika TI - Autoimmune Progressive Fibrosing Interstitial Lung Disease: Predictors of Fast Decline JF - FRONTIERS IN PHARMACOLOGY J2 - FRONT PHARMACOL VL - 12 PY - 2021 PG - 10 SN - 1663-9812 DO - 10.3389/fphar.2021.778649 UR - https://m2.mtmt.hu/api/publication/32551601 ID - 32551601 N1 - Department of Pulmonology, Semmelweis University, Budapest, Hungary Medical Imaging Centre, Semmelweis University, Budapest, Hungary Department of Genetics, Cell, - and Immunobiology, Semmelweis University, Budapest, Hungary Department of Rheumatology and Clinical Immunology, Semmelweis University, Budapest, Hungary Department of Clinical Immunology, Adult and Pediatric Rheumatology, National Institute of Locomotor Diseases and Disabilities, Budapest, Hungary 3rd Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary Cited By :2 Export Date: 14 November 2022 Correspondence Address: Müller, V.; Department of Pulmonology, Hungary; email: muller.veronika@med.semmelweis-univ.hu LA - English DB - MTMT ER - TY - GEN AU - Nagy, Tamás AU - Nagy, Alexandra AU - Eszes, Noémi AU - Bohács, Anikó AU - Palmer, Erik József AU - Bárczi, Enikő AU - Kolonics-Farkas, Abigél Margit AU - Tárnoki, Ádám Domonkos AU - Tárnoki, Dávid László AU - Karlinger, Kinga AU - Müller, Veronika AU - Vincze, Krisztina TI - Szisztémás autoimmun kórkép- interstitialis tüdőbetegség (CTD-ILD) hazai betegjellemzői és terápiás lehetőségek. A MAGYAR TÜDŐGYÓGYÁSZ TÁRSASÁG ALLERGOLÓGIAI ÉS LÉGZÉSPATHOLÓGIAI, VALAMINT ILD SZEKCIÓINAK TUDOMÁNYOS ÜLÉSE 2021.05.27-29. TS - A MAGYAR TÜDŐGYÓGYÁSZ TÁRSASÁG ALLERGOLÓGIAI ÉS LÉGZÉSPATHOLÓGIAI, VALAMINT ILD SZEKCIÓINAK TUDOMÁNYOS ÜLÉSE 2021.05.27-29. PY - 2021 UR - https://m2.mtmt.hu/api/publication/32061688 ID - 32061688 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Kolonics-Farkas, Abigél Margit AU - Jáky-Kováts, Zsuzsanna Ágnes AU - Bohács, Anikó AU - Odler, Balázs AU - Benke, Kálmán AU - Ágg, Bence AU - Szabolcs, Zoltán AU - Müller, Veronika TI - Airway obstruction can be better predicted using Global Lung Function Initiative spirometry reference equations in Marfan syndrome JF - PHYSIOLOGY INTERNATIONAL J2 - PHYSIOL INT VL - 108 PY - 2021 IS - 1 SP - 95 EP - 105 PG - 11 SN - 2498-602X DO - 10.1556/2060.2021.00002 UR - https://m2.mtmt.hu/api/publication/31936034 ID - 31936034 N1 - Department of Pulmonology, Semmelweis University, Budapest, Hungary Division of Nephrology, Department of Internal Medicine, Medical University of Graz, Graz, Austria Heart and Vascular Center, Semmelweis University, Budapest, Hungary Hungarian Marfan Foundation, Budapest, Hungary Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary Export Date: 17 November 2022 Correspondence Address: Kolonics-Farkas, A.M.; Department of Pulmonology, Hungary Tomoutca 25-29, Hungary; email: kolonics-farkas.abigel@med.semmelweis-univ.hu LA - English DB - MTMT ER - TY - JOUR AU - Nagy, Alexandra AU - Bárczi, Enikő AU - Kolonics-Farkas, Abigél Margit AU - Bohács, Anikó AU - Vincze, Krisztina AU - Eszes, Noémi AU - Erdélyi, Tamás AU - Tárnoki, Ádám Domonkos AU - Tárnoki, Dávid László AU - Müller, Veronika TI - Effect of Antifibrotic Therapies in Patients with Interstitial Pneumonia with Autoimmune Features JF - EUROPEAN RESPIRATORY JOURNAL J2 - EUR RESPIR J VL - 56 PY - 2020 IS - Suppl. 64 SN - 0903-1936 DO - 10.1183/13993003.congress-2020.738 UR - https://m2.mtmt.hu/api/publication/32856966 ID - 32856966 LA - English DB - MTMT ER - TY - JOUR AU - Kolonics-Farkas, Abigél Margit AU - Müller, Veronika TI - Az interstitialis tüdőbetegségek diagnosztikája és az idiopathiás tüdőfibrosis kezelése felnőttekben JF - ORVOSKÉPZÉS J2 - ORVOSKÉPZÉS VL - 95 PY - 2020 IS - 4 SP - 609 EP - 615 PG - 7 SN - 0030-6037 UR - https://m2.mtmt.hu/api/publication/31819317 ID - 31819317 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Kolonics-Farkas, Abigél Margit AU - Sterclova, Martina AU - Mogulkoc, Nesrin AU - Kus, Jan AU - Hajkova, Marta AU - Müller, Veronika AU - Jovanovic, Dragana AU - Tekavec-Trkanjec, Jasna AU - Littnerova, Simona AU - Hejduk, Karel AU - Vasakova, Martina TI - Anticoagulant Use and Bleeding Risk in Central European Patients with Idiopathic Pulmonary Fibrosis (IPF) Treated with Antifibrotic Therapy: Real-World Data from EMPIRE JF - DRUG SAFETY J2 - DRUG SAFETY VL - 43 PY - 2020 IS - 10 SP - 971 EP - 980 PG - 10 SN - 0114-5916 DO - 10.1007/s40264-020-00978-5 UR - https://m2.mtmt.hu/api/publication/31479556 ID - 31479556 N1 - Department of Pulmonology, Semmelweis University, Tömő utca 25-29, Budapest, 1083, Hungary Department of Respiratory Diseases of the First Faculty of Medicine, Charles University, Thomayer Hospital, Prague, Czech Republic Department of Pulmonary Medicine, Ege University Medical School, Izmir, Turkey Department of Pulmonary Diseases, Institute of Tuberculosis and Lung Diseases, Warsaw, Poland Clinic of Pneumology and Phthisiology, University Hospital Bratislava, Bratislava, Slovakia University Hospital of Pulmonology, Clinical Center of Serbia, Belgrade, Serbia Pulmonary Department, University Hospital Dubrava, Zagreb, Croatia Institute of Biostatistics and Analyses, Masaryk University, Faculty of Medicine, Brno, Czech Republic Cited By :6 Export Date: 11 November 2022 CODEN: DRSAE Correspondence Address: Kolonics-Farkas, A.M.; Department of Pulmonology, Tömő utca 25-29, Hungary; email: kolonics-farkas.abigel@med.semmelweis-univ.hu AB - Introduction Nintedanib, a tyrosine kinase receptor inhibitor, may be associated with increased bleeding risk. Thus, patients with an inherited predisposition to bleeding, or those receiving therapeutic doses of anticoagulants or high-dose antiplatelet therapy, have been excluded from clinical trials of nintedanib in idiopathic pulmonary fibrosis (IPF). Objective Our objective was to examine real-world bleeding events in patients with IPF treated with antifibrotics, including those receiving anticoagulants and/or antiplatelet therapy. Methods The European MultiPartner IPF Registry (EMPIRE) enrolled 2794 patients with IPF: group A (1828: no anticoagulant or antiplatelet treatment), group B (227: anticoagulant treatment), group C (659: antiplatelet treatment), and group D (80: anticoagulant and antiplatelet treatment). Overall, 673 (24.1%) received nintedanib and 933 (33.4%) received pirfenidone. Bleeding events and their relationship to antifibrotic and anticoagulation treatment were characterized. Results Group A patients, versus those in groups B, C, and D, were typically younger and generally had the lowest comorbidity rates. A higher proportion of patients in groups A and C, versus group B, received nintedanib. Pirfenidone, most common in group D, was more evenly balanced across groups. In patients with reported bleeding events, seven of eight received nintedanib (groups A, C, and D). Bleeding incidence was 3.0, 0, 1.3, and 18.1 per 10,000 patient-years (groups A, B, C, and D, respectively). Conclusion Real-world data from EMPIRE showed that patients on anticoagulant medications received nintedanib less frequently, perhaps based on its mechanism of action. Overall, bleeding incidence was low (0.29%: nintedanib 0.25%; pirfenidone 0.04%) and irrespective of anticoagulant or antiplatelet therapy received (P = 0.072). LA - English DB - MTMT ER -